151
|
Richette P, Tubach F, Breban M, Viguier M, Bachelez H, Bardin T, Dougados M. Le psoriasis est un facteur de sévérité chez les malades ayant des rachialgies inflammatoires récentes : données issues de la cohorte DESIR. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
152
|
|
153
|
Monfort JB, Pagès C, Schneider P, Neyns B, Comte C, Bagot M, Vignon-Pennamen MD, Viguier M, Lebbé C. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res 2012; 22:399-401. [DOI: 10.1097/cmr.0b013e3283570792] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
154
|
Dieude P, Sbidian E, Viguier M, Zafrani E, de Bazelaire C, Dawidowicz K, Adle-Biassette H, Allez M, Petit A, Richette P, Bachelez H. Neutrophilic cholangitis in psoriasis vulgaris and psoriatic arthritis. Br J Dermatol 2012; 168:216-8. [PMID: 22971251 DOI: 10.1111/j.1365-2133.2012.11157.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
155
|
Pécuchet N, Lebbe C, Mir O, Billemont B, Blanchet B, Franck N, Viguier M, Coriat R, Tod M, Avril MF, Goldwasser F. Sorafenib in advanced melanoma: a critical role for pharmacokinetics? Br J Cancer 2012; 107:455-61. [PMID: 22767146 PMCID: PMC3405224 DOI: 10.1038/bjc.2012.287] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 05/16/2012] [Accepted: 05/30/2012] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND Inter-patient pharmacokinetic variability can lead to suboptimal drug exposure, and therefore might impact the efficacy of sorafenib. This study reports long-term pharmacokinetic monitoring of patients treated with sorafenib and a retrospective pharmacodynamic/pharmacokinetic analysis in melanoma patients. PATIENTS AND METHODS Heavily pretreated patients with stage IV melanoma were started on sorafenib 400 mg twice daily (bid). In the absence of limiting toxicity, dose escalation of 200 mg bid levels was done every 2 weeks. Plasma sorafenib measurement was performed at each visit, allowing a retrospective pharmacodynamic/pharmacokinetic analysis for safety and efficacy. RESULTS In all, 19 of 30 patients underwent dose escalation over 400 mg bid, and 28 were evaluable for response. The overall disease control rate was 61% (95% confidence interval (CI): 42.6-78.8), including three confirmed responses (12%). Disease control rate and progression-free survival (PFS) were improved in patients with high vs low exposure (80% vs 32%, P=0.02, and 5.25 vs 2.5 months, P=0.005, hazard ratio (HR)=0.28 (95% CI: 0.11-0.73)). In contrast, drug dosing had no effect on PFS. In multivariate analysis, drug exposure was the only factor associated with PFS (HR=0.36 (95% CI: 0.13-0.99)). Diarrhoea and anorexia were correlated with drug dosing, while hypertension and hand-foot skin reaction were correlated with drug exposure. CONCLUSIONS Although sorafenib had modest efficacy in melanoma, these results suggest a correlation between exposure and efficacy of sorafenib. Therefore, dose optimisation in patients with low exposure at standard doses should be evaluated in validated indications.
Collapse
Affiliation(s)
- N Pécuchet
- Department of Medical Oncology, Centre for Research on Angiogenesis Inhibitors (CERIA), Cochin Teaching Hospital, Université Paris Descartes, Sorbonne Paris Cité, AP-HP, 27, rue du faubourg Saint Jacques, F75014 Paris, France
| | - C Lebbe
- Department of Dermatology and INSERM U976, Saint Louis Teaching Hospital, Université Paris Diderot, AP-HP, Paris, France
| | - O Mir
- Department of Medical Oncology, Centre for Research on Angiogenesis Inhibitors (CERIA), Cochin Teaching Hospital, Université Paris Descartes, Sorbonne Paris Cité, AP-HP, 27, rue du faubourg Saint Jacques, F75014 Paris, France
| | - B Billemont
- Department of Medical Oncology, Centre for Research on Angiogenesis Inhibitors (CERIA), Cochin Teaching Hospital, Université Paris Descartes, Sorbonne Paris Cité, AP-HP, 27, rue du faubourg Saint Jacques, F75014 Paris, France
| | - B Blanchet
- Department of Pharmacy, Cochin Teaching Hospital, AP-HP, Paris, France
| | - N Franck
- Department of Dermatology, Cochin Teaching Hospital, Université Paris Descartes, Sorbonne Paris Cité, AP-HP, Paris, France
| | - M Viguier
- Department of Dermatology and INSERM U976, Saint Louis Teaching Hospital, Université Paris Diderot, AP-HP, Paris, France
| | - R Coriat
- Department of Medical Oncology, Centre for Research on Angiogenesis Inhibitors (CERIA), Cochin Teaching Hospital, Université Paris Descartes, Sorbonne Paris Cité, AP-HP, 27, rue du faubourg Saint Jacques, F75014 Paris, France
| | - M Tod
- Department of Pharmacy, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Université de Lyon, Lyon, France
| | - M-F Avril
- Department of Dermatology, Cochin Teaching Hospital, Université Paris Descartes, Sorbonne Paris Cité, AP-HP, Paris, France
| | - F Goldwasser
- Department of Medical Oncology, Centre for Research on Angiogenesis Inhibitors (CERIA), Cochin Teaching Hospital, Université Paris Descartes, Sorbonne Paris Cité, AP-HP, 27, rue du faubourg Saint Jacques, F75014 Paris, France
| |
Collapse
|
156
|
Viguier M, Pagès C, Aubin F, Delaporte E, Descamps V, Lok C, Beylot-Barry M, Séneschal J, Dubertret L, Morand JJ, Dréno B, Bachelez H. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol 2012; 167:417-23. [DOI: 10.1111/j.1365-2133.2012.10940.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
157
|
Richette P, Tubach F, Breban M, Viguier M, Bachelez H, Bardin T, Dougados M. Psoriasis and phenotype of patients with early inflammatory back pain. Ann Rheum Dis 2012; 72:566-71. [DOI: 10.1136/annrheumdis-2012-201610] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
158
|
Saussine A, Gueguen A, de Menthon M, Maisonobe T, Battistella M, Serrato T, Bagot M, Lebbé C, Mahr A, Viguier M. Sweet syndrome revealing microscopic polyangiitis. Rheumatology (Oxford) 2012; 51:1916-7. [PMID: 22513149 DOI: 10.1093/rheumatology/kes060] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
159
|
Pagès C, Misset JL, de Kerviler E, Bavoux F, Fernandez H, Viguier M. [Melanoma during pregnancy]. Ann Dermatol Venereol 2012; 139:298-304; quiz 296-7, 306-7. [PMID: 22482486 DOI: 10.1016/j.annder.2012.01.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2011] [Revised: 12/30/2011] [Accepted: 01/12/2012] [Indexed: 10/28/2022]
Affiliation(s)
- C Pagès
- Service de dermatologie, hôpital Saint-Louis, AP-HP, 1 avenue Claude-Vellefaux, Paris cedex 10, France
| | | | | | | | | | | |
Collapse
|
160
|
Adamski H, Viguier M. L’urticaire solaire. Pré-test. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
161
|
Adamski H, Viguier M. L’urticaire solaire. Ann Dermatol Venereol 2012; 139:324-8; quiz 323, 330. [DOI: 10.1016/j.annder.2012.01.020] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2011] [Revised: 01/19/2012] [Accepted: 01/31/2012] [Indexed: 11/29/2022]
|
162
|
Pagès C, Misset JL, de Kerviler E, Bavoux F, Fernandez H, Viguier M. Mélanome et grossesse. Réponses au pré-test. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
163
|
Pagès C, Misset JL, de Kerviler E, Bavoux F, Fernandez H, Viguier M. Mélanome et grossesse. Pré-test. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.01.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
164
|
Pham T, Bachelez H, Berthelot JM, Blacher J, Claudepierre P, Constantin A, Fautrel B, Gaujoux-Viala C, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Lequerré T, Marolleau JP, Martinez V, Masson C, Mouthon L, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. Abatacept therapy and safety management. Joint Bone Spine 2012; 79 Suppl 1:3-84. [DOI: 10.1016/s1297-319x(12)70011-8] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
165
|
Pages C, Viguier M, Comte C, Baccard M, Archimbaud A, Madjlessi N, Kerob D, Madelaine I, Mourah S, Bagot M, Lebbe C. Toxicité cutanée et inhibiteurs de BRAF. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.10.371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
166
|
Bounfour T, Bouaziz JD, Petit A, Bézier M, Viguier M, Rybojad M, Bagot M. Efficacité des immunoglobulines intraveineuses au cours des vasculites livédoïdes ulcérées : quatre cas. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.10.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
167
|
Ellouadghiri A, Bézier M, Bohelay G, Ménasché S, Mourah S, Bagot M, Viguier M, Pages C, Lebbé C. Premier cas d’hypertension artérielle pulmonaire sévère et réversible induite par le dasatinib au cours du traitement d’un mélanome métastatique. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.10.383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
168
|
Saussine A, Gueguen A, de Menthon M, Battistella M, Maisonobe T, Bagot M, Lebbé C, Viguier M. Syndrome de Sweet révélant une micropolyangéite : première description. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.10.345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
169
|
Morice C, Joly F, Bagot M, Vignon-Pennamen MD, Viguier M. Manifestations cutanées de la maladie de Waldmann : un diagnostic difficile. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.10.353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
170
|
Pages C, Gornet J, Monsel G, Ram Wolff C, Bagot M, Lebbe C, Viguier M. Colite sous ipilimumab traitée par infliximab. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.10.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
171
|
Ram-Wolff C, Pagès C, Viguier M, Lebbé C, Comte C, Bagot M, Bouche C. Diagnostic et prise en charge de l’hypophysite auto-immune à l’ipilimumab : à propos de trois cas. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.10.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
172
|
Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011; 78 Suppl 1:15-185. [PMID: 21703545 DOI: 10.1016/s1297-319x(11)70001-x] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVES To develop and/or update fact sheets about TNFα antagonists treatments, in order to assist physicians in the management of patients with inflammatory joint disease. METHODS 1. selection by a committee of rheumatology experts of the main topics of interest for which fact sheets were desirable; 2. identification and review of publications relevant to each topic; 3. development and/or update of fact sheets based on three levels of evidence: evidence-based medicine, official recommendations, and expert opinion. The experts were rheumatologists and invited specialists in other fields, and they had extensive experience with the management of chronic inflammatory diseases, such as rheumatoid. They were members of the CRI (Club Rhumatismes et Inflammation), a section of the Société Francaise de Rhumatologie. Each fact sheet was revised by several experts and the overall process was coordinated by three experts. RESULTS Several topics of major interest were selected: contraindications of TNFα antagonists treatments, the management of adverse effects and concomitant diseases that may develop during these therapies, and the management of everyday situations such as pregnancy, surgery, and immunizations. After a review of the literature and discussions among experts, a consensus was developed about the content of the fact sheets presented here. These fact sheets focus on several points: 1. in RA and SpA, initiation and monitoring of TNFα antagonists treatments, management of patients with specific past histories, and specific clinical situations such as pregnancy; 2. diseases other than RA, such as juvenile idiopathic arthritis; 3. models of letters for informing the rheumatologist and general practitioner; 4. and patient information. CONCLUSION These TNFα antagonists treatments fact sheets built on evidence-based medicine and expert opinion will serve as a practical tool for assisting physicians who manage patients on these therapies. They will be available continuously at www.cri-net.com and updated at appropriate intervals.
Collapse
Affiliation(s)
- Thao Pham
- Rheumatology Department, CHU Sainte-Marguerite, Marseille, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
173
|
Adamski H, Bedane C, Bonnevalle A, Thomas P, Peyron JL, Rouchouse B, Cambazard F, Jeanmougin M, Viguier M. Solar urticaria treated with intravenous immunoglobulins. J Am Acad Dermatol 2011; 65:336-340. [DOI: 10.1016/j.jaad.2010.05.040] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2010] [Revised: 05/11/2010] [Accepted: 05/20/2010] [Indexed: 11/15/2022]
|
174
|
Battistella M, Robert C, Gossot D, Dupuy A, Mateus C, Kérob D, Avril M, Basset-Seguin N, Lebbé C, de Kerviler E, Viguier M. Visceral lesions occurring during follow-up of melanoma patients: a true place for other diagnosis than melanoma metastasis. J Eur Acad Dermatol Venereol 2011; 26:602-10. [DOI: 10.1111/j.1468-3083.2011.04129.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
175
|
Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, Triebel F, Charron D, Aoudjit F, Al-Daccak R, Michel L. MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis. J I 2011; 186:5173-83. [DOI: 10.4049/jimmunol.1002050] [Citation(s) in RCA: 139] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
176
|
Viguier M, Guigue P, Pagès C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 2010; 153:66-7. [PMID: 20621920 DOI: 10.7326/0003-4819-153-1-201007060-00030] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
177
|
Khoudri I, Frémont G, Flageul B, Brière J, Dubertret L, Viguier M. [Bilateral inguinal lymphadenopathy and erythema nodosum: an uncommon presentation of cat scratch disease]. Rev Med Interne 2010; 32:e34-6. [PMID: 20646798 DOI: 10.1016/j.revmed.2009.11.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2009] [Revised: 09/14/2009] [Accepted: 11/25/2009] [Indexed: 10/19/2022]
Abstract
Cat scratch disease is usually revealed by a proximal lymphadenopathy related to the inoculation site. We report a 22-year-old female who presented with erythema nodosum and bilateral inguinal lymphadenopathy. Serologic test and lymph node PCR detection for Bartonella henselae were negative. Nevertheless, the patient received doxycycline and clinical manifestations rapidly resolved. A follow-up detection of IgM and IgG against Bartonella henselae performed 1 month later was positive. This case report illustrates an original presentation of cat scratch disease and reminds us the lack of sensitivity of laboratory investigations.
Collapse
Affiliation(s)
- I Khoudri
- Service de dermatologie, université Paris-VII Denis-Diderot, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, 1 avenue Claude-Vellefaux, Paris cedex 10, France
| | | | | | | | | | | |
Collapse
|
178
|
Viguier M, Richette P, Bachelez H, Wendling D, Aubin F. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol 2010; 5:421-31. [PMID: 20477038 DOI: 10.1586/eci.09.18] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
TNF-alpha antagonists have been shown to be very effective for the treatment of various rheumatic and nonrheumatic diseases, including psoriasis, and for off-label use in other inflammatory and immune-mediated disorders. However, the increasing use of these agents has led to the recognition of several paradoxical cutaneous adverse effects. New onset or exacerbation of cutaneous psoriasis, cutaneous vasculitis and sarcoidosis have been described. Further characterization and more precise diagnosis of these adverse events are warranted to provide further insights into the pathogenic mechanisms involved and to optimize their management. Herein, we present a review of the different clinical patterns of these paradoxical cutaneous adverse disorders, and we propose recommendations for their management.
Collapse
Affiliation(s)
- Manuelle Viguier
- Université Paris 7, Inserm U697 and Department of Dermatology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
| | | | | | | | | |
Collapse
|
179
|
Pécuchet N, Avril M, Kerob D, Billemont B, Blanchet B, Herait P, Gorin I, Viguier M, Lebbé C, Goldwasser F. Relationship between dose, exposure, and antitumoral activity of sorafenib in melanoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8582] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
180
|
Do-Pham G, Pagès C, Picard C, Galicier L, Lémann M, Dubertret L, Viguier M. A first case report of a patient with paraneoplastic dermatomyositis developing diffuse alveolar haemorrhage. Br J Dermatol 2010; 163:227-8. [PMID: 20394626 DOI: 10.1111/j.1365-2133.2010.09800.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
181
|
Affiliation(s)
- Manuelle Viguier
- Department of Dermatology, Université Paris Diderot-Paris 7, and Hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, Paris, France
| | | |
Collapse
|
182
|
Viguier M, Pouthier F, Tiberghien P, Aubin F. La photochimiothérapie extracorporelle. Transfus Clin Biol 2010; 17:28-33. [DOI: 10.1016/j.tracli.2009.10.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2009] [Accepted: 10/23/2009] [Indexed: 11/15/2022]
|
183
|
Viguier M, Richette P, Bachelez H, Wendling D, Aubin F. Manifestations cutanées paradoxales des anti-TNF-alpha. Ann Dermatol Venereol 2010; 137:64-71; quiz 63, 78-9. [DOI: 10.1016/j.annder.2009.10.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2009] [Accepted: 07/04/2009] [Indexed: 11/16/2022]
|
184
|
Fardet L, Galicier L, Vignon-Pennamen MD, Regnier S, Noguera M, De Labarthe A, Raffoux E, Martinez V, Buyse S, Viguier M, Osio A, Lebbé C, Morel P, Dupuy A, Rybojad M. Frequency, clinical features and prognosis of cutaneous manifestations in adult patients with reactive haemophagocytic syndrome. Br J Dermatol 2009; 162:547-53. [DOI: 10.1111/j.1365-2133.2009.09549.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
185
|
Wu YL, Hauptmann G, Viguier M, Yu CY. Molecular basis of complete complement C4 deficiency in two North-African families with systemic lupus erythematosus. Genes Immun 2009; 10:433-45. [PMID: 19279649 PMCID: PMC2767122 DOI: 10.1038/gene.2009.10] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2008] [Revised: 02/03/2009] [Accepted: 02/03/2009] [Indexed: 11/09/2022]
Abstract
Complete deficiency of complement C4 is among the strongest genetic risk factors for human systemic lupus erythematosus (SLE). C4 is a constituent of the RP-C4-CYP21-TNX (RCCX) module in the human leukocyte antigen (HLA) that exhibits inter-individual copy-number and gene-size variations. Here, we studied two North-African families with complete C4 deficiency and SLE. The first included a Moroccan male SLE patient (1P) and a sibling, who were both homozygous for HLA-A*02 B*17 DRB1*07. The second had an Algerian female SLE patient (2P) homozygous for HLA-A*01 B*17 DRB1*13. Early SLE disease onset, the presence of photosensitive rashes, anti-Ro/SSA, renal disease and high titers of antinuclear antibodies were the common features of complete C4 deficiency. Southern blot analyses showed that 1P had monomodular RCCX with a long C4A, whereas 2P had bimodular RCCX with one long C4A and one short C4B. Genomic DNA fragments for these mutant genes were amplified and sequenced. A C>T transition that created the R540X nonsense mutation in C4A was found in 1P. An identical 4-bp insertion that generated the Y1537X nonsense mutation was discovered in both C4A and C4B of 2P. The high concordance of SLE and C4 deficiency among patients with non-DR3 and non-DR2 haplotypes underscores the importance of C4 proteins in the protection against SLE.
Collapse
Affiliation(s)
- Yee Ling Wu
- Center for Molecular and Human Genetics, the Research Institute at Nationwide Children’s Hospital, Columbus, Ohio
- Integrated Biomedical Science Graduate Program, The Ohio State University, Columbus, Ohio
| | - Georges Hauptmann
- Laboratoire d’Immunogenetique Moleculaire, Universite Louis Pasteur, Strasbourg, Cedex, France
| | - Manuelle Viguier
- Service de Dermatologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - C. Yung Yu
- Center for Molecular and Human Genetics, the Research Institute at Nationwide Children’s Hospital, Columbus, Ohio
- Integrated Biomedical Science Graduate Program, The Ohio State University, Columbus, Ohio
- Department of Pediatrics, The Ohio State University, 700 Children’s Drive, Columbus, Ohio 43205, USA
- Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, 700 Children’s Drive, Columbus, Ohio 43205, USA
| |
Collapse
|
186
|
Pagès C, Robert C, Thomas L, Maubec E, Sassolas B, Granel-Brocard F, Chevreau C, De Raucourt S, Leccia MT, Fichet D, Khammari A, Boitier F, Stoebner PE, Dalac S, Celerier P, Aubin F, Viguier M. Management and outcome of metastatic melanoma during pregnancy. Br J Dermatol 2009; 162:274-81. [DOI: 10.1111/j.1365-2133.2009.09240.x] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
187
|
Maksimovic L, Frémont G, Jeanmougin M, Dubertret L, Viguier M. Solar Urticaria Successfully Treated with Intravenous Immunoglobulins. Dermatology 2009; 218:252-4. [DOI: 10.1159/000193998] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2008] [Accepted: 10/27/2008] [Indexed: 11/19/2022] Open
|
188
|
Gressier L, Pruvost-Balland C, Dubertret L, Viguier M. Syndrome d’hypersensibilité médicamenteuse induit par l’atorvastatine. Ann Dermatol Venereol 2009; 136:50-3. [DOI: 10.1016/j.annder.2008.07.063] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2008] [Accepted: 07/11/2008] [Indexed: 12/01/2022]
|
189
|
Gener G, Dupuy A, Rouveau M, Claisse JP, Casin I, Dubertret L, Morel P, Simon F, Viguier M. [Systematic screening for methicillin-resistant Staphylococcus aureus (MRSA) in the nasal cavities of patients hospitalized in the dermatology departments of the Saint-Louis Hospital]. Ann Dermatol Venereol 2008; 135:815-21. [PMID: 19084690 DOI: 10.1016/j.annder.2008.09.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2008] [Accepted: 09/12/2008] [Indexed: 11/19/2022]
Abstract
OBJECTIVES In a bid to combat methicillin-resistant Staphylococcus aureus (MRSA) more efficiently in our department, we performed a study to 1) clarify the MRSA carriage rate in patients hospitalized in the department; 2) evaluate the rate of MRSA acquisition during hospitalization; 3) describe the MRSA carrier profile; 4) study the morbidity and mortality associated with MRSA. PATIENTS AND METHODS We conducted a three-month prospective study in all patients hospitalized for more than 24hours in the dermatology department of the Saint-Louis Hospital. Nasal swab cultures were performed on the day of admission, once a week thereafter and on the day of discharge. Clinical and epidemiological data were individually reviewed by means of a standardized questionnaire. RESULTS In 310 patients, the prevalence of nasal MRSA carriage at admission was 6.5%. During hospitalization, 1.9% of our patients became colonized with MRSA. MRSA carriers were significantly older than non-carriers and had been hospitalized more frequently over the previous 12 months, principally in intensive care or in intermediate or long-term care facilities, and erosive and/or ulcerated dermatitis was more common in this population. Of the 27 patients colonized with MRSA, only three had MRSA infections, and these were successfully treated with antibiotics. DISCUSSION The observed rate of MRSA carriage was close to that seen in intensive care units (7%). While systematic screening for MRSA in patients with erosive and/or ulcerated dermatitis would allow detection of twice as many cases of MRSA than the usual screening recommendations, this would be associated with little tangible benefit and high costs, and we therefore decided not to change the usual MRSA screening politic in our dermatology department.
Collapse
Affiliation(s)
- G Gener
- Service de dermatologie, université Paris-VII Denis-Diderot, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, 1, avenue Claude-Vellefaux, 75475 Paris cedex 10, France
| | | | | | | | | | | | | | | | | |
Collapse
|
190
|
Battistella M, Frémont G, Vignon-Pennamen MD, Gornet JM, Dubertret L, Viguier M. Imatinib-Induced Hand-Foot Syndrome in a Patient With Metastatic Gastrointestinal Stromal Tumor. ACTA ACUST UNITED AC 2008; 144:1400-2. [DOI: 10.1001/archderm.144.10.1400] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
191
|
Viguier M, Richette P, Aubin F, Beylot-Barry M, Lahfa M, Bedane C, Delesalle F, Richard-Lallemand MA, Delaporte E, Dubertret L, Bardin T, Bachelez H. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. ACTA ACUST UNITED AC 2008; 58:1796-802. [PMID: 18512820 DOI: 10.1002/art.23507] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVE To investigate the nature of polyarthritis in patients with moderate to severe psoriasis undergoing treatment with efalizumab, a humanized anti-CD11a monoclonal antibody. METHODS In a multicenter study, we retrospectively analyzed patients who developed arthritis during treatment with efalizumab. The relationship between joint manifestations and psoriatic disease was addressed by using different classification criteria for psoriatic arthritis (PsA). The course of arthritis and its response to treatment were also investigated. RESULTS Sixteen patients developed de novo inflammatory rheumatic disease, with a mean delay of 15 weeks following the start of treatment, and with exclusive asymmetric peripheral monarthritis or oligoarthritis (8 patients), inflammatory spinal disease (1 patient), or both (7 patients), associated in some cases with enthesitis and dactylitis. All patients fulfilled at least 2 different sets of classification criteria for PsA. In most of them, an improvement in skin lesions was observed at the onset of PsA, as measured using the Psoriasis Area and Severity Index (mean score 24.88 before efalizumab versus 18.78 at the time of arthritis). Efalizumab treatment was stopped in 11 patients and was followed by the elimination of rheumatologic symptoms in 1 patient, while 8 patients required treatment with nonsteroidal antiinflammatory drugs with or without methotrexate, with 2 later being switched to tumor necrosis factor alpha inhibitors. Reintroduction of efalizumab (2 patients) was followed by a relapse of PsA. CONCLUSION This study questions the role of efalizumab in the induction of PsA. It also emphasizes the discrepancy between the courses of psoriatic skin and joint manifestations under treatment. Prospective case-control studies are needed to accurately investigate the impact of efalizumab on PsA.
Collapse
Affiliation(s)
- Manuelle Viguier
- Unité INSERM U697, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, and Université Paris 7, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
192
|
Knol AC, Lemaître F, Pandolfino MC, Volteau C, Quéreux G, Saiagh S, Khammari A, Viguier M, Dréno B. Absence of amplification of CD4+CD25highregulatory T cells duringin vitroexpansion of tumor-infiltrating lymphocytes in melanoma patients. Exp Dermatol 2008; 17:436-45. [DOI: 10.1111/j.1600-0625.2007.00681.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
193
|
Choffray A, Flageul B, Dubertret L, Viguier M. [Erysipelas-like dermatitis of the legs revealing aspergilloma of the maxillary sinus]. Ann Dermatol Venereol 2007; 134:851-4. [PMID: 18033066 DOI: 10.1016/s0151-9638(07)92830-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Skin signs is associated with Aspergillus are rare and are seen principally in immunodepressed patients. Distinction is generally made between primary skin aspergillosis, caused by direct cutaneous inoculation with the offending organism, and secondary skin aspergillosis, associated with peripheral emboli from an area of chronic pulmonary or sinus mycetoma. There have been rare reports of indirect satellite skin signs resulting from Aspergillus infection, and below we present such a case. PATIENTS AND METHODS A 40 year-old immunocompetent man consulted for erysipeloid plaques on the lower limbs recurring over a period of seven months. X-rays and CAT scans of the sinus demonstrated asymptomatic axillary sinusitis probably caused by Aspergillus. The diagnosis was confirmed by surgery, which resulted in cure without additional antifungal treatment. The inflammatory syndrome subsided and after 15 months, there was no recurrence of lesions. DISCUSSION The absence of relapse following treatment of the focus of aspergillosis forms a major argument in favour of a causal relationship between the erysipeloid dermatitis and the sinus mycotic infection. The hypothesis of a septic embologenic mechanism within the sinus was abandoned in favour of a mechanism similar to streptococcal nodular erythema, seen in diseases involving immune complexes, possibly caused by allergy to Aspergillus proteins. This case history demonstrates the existence of satellite skin signs of Aspergillus infection indicative of neither primary nor secondary aspergillosis.
Collapse
Affiliation(s)
- A Choffray
- Service de Dermatologie, Hôpital Saint-Louis, Université Denis-Diderot Paris VII, Paris
| | | | | | | |
Collapse
|
194
|
Fazilleau N, Bachelez H, Gougeon ML, Viguier M. Cutting edge: size and diversity of CD4+CD25high Foxp3+ regulatory T cell repertoire in humans: evidence for similarities and partial overlapping with CD4+CD25- T cells. J Immunol 2007; 179:3412-6. [PMID: 17785774 DOI: 10.4049/jimmunol.179.6.3412] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Both differentiation and function of CD4+CD25(high) naturally arising regulatory T cells (Treg), which play a key role in the control of autoimmunity, are thought to depend on TCR specificity. In the present study, we comparatively measured the alphabetaTCR repertoire sizes of human peripheral blood Treg and CD4+CD25- T cells by using a methodology based on PCR amplification and sequencing analysis. We show that Treg use a large unrestricted alphabeta TCR repertoire, the size and diversity of which are closely similar to those of CD4+CD25- T cells, with a mean estimated size of 3.5 x 10(6) distinct alphabeta TCR vs 4.7 x 10(6) distinct alphabetaTCR for CD4+CD25- T cells. In addition, a 24% overlap between the repertoires of these two CD4+ subsets in the periphery is found. These data emphasize the intersection between naturally occurring Treg and effector T cell peripheral repertoires and provide new insights into the ontogeny of Treg in humans.
Collapse
MESH Headings
- Biomarkers/metabolism
- Cell Separation
- Cell Size
- Clone Cells
- Cloning, Molecular
- Forkhead Transcription Factors/biosynthesis
- Gene Rearrangement, beta-Chain T-Cell Antigen Receptor
- Humans
- Immunosuppression Therapy
- Interleukin-2 Receptor alpha Subunit/biosynthesis
- Interleukin-2 Receptor alpha Subunit/deficiency
- Receptors, Antigen, T-Cell, alpha-beta/biosynthesis
- Receptors, Antigen, T-Cell, alpha-beta/genetics
- Sequence Analysis, DNA
- T-Lymphocyte Subsets/cytology
- T-Lymphocyte Subsets/immunology
- T-Lymphocyte Subsets/metabolism
- T-Lymphocytes, Regulatory/cytology
- T-Lymphocytes, Regulatory/immunology
- T-Lymphocytes, Regulatory/metabolism
Collapse
Affiliation(s)
- Nicolas Fazilleau
- Unité de Recherche et d'Expertise Immunité Anti-virale, Biothérapie et Vaccins, Institut National de la Santé et de la Recherche Médicale (INSERM) U668, Institut Pasteur, France.
| | | | | | | |
Collapse
|
195
|
Viguier M, Jeanmougin M, Begon E, Verola O, Dubertret L, Bachelez H. Remission of photosensitivity following treatment of psoriasis vulgaris with tumour necrosis factor inhibitors. Br J Dermatol 2007; 157:625-7. [PMID: 17596163 DOI: 10.1111/j.1365-2133.2007.08041.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
196
|
Duong T, Marrache F, Nachury M, Dubertret L, Lémann M, Viguier M. Syndrome de Cronkhite et Canada. Ann Dermatol Venereol 2007; 134:709-10. [DOI: 10.1016/s0151-9638(07)91845-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
197
|
Zuber J, Viguier M, Lemaitre F, Senée V, Patey N, Elain G, Geissmann F, Fakhouri F, Ferradini L, Julier C, Bandeira A. Severe FOXP3+ and naïve T lymphopenia in a non-IPEX form of autoimmune enteropathy combined with an immunodeficiency. Gastroenterology 2007; 132:1694-704. [PMID: 17484867 DOI: 10.1053/j.gastro.2007.02.034] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND & AIMS Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is the best-characterized form of a rare entity called autoimmune enteropathy (AIE). IPEX syndrome is due to mutations in the FOXP3 gene, a transcription factor essential for the development and function of the natural regulatory CD25(+)CD4(+) T cells. We studied a female patient with a polyautoimmune AIE syndrome resembling a mild form of IPEX syndrome but associated with recurrent bacterial infections and mild hypogammaglobulinemia. We hypothesized that this syndrome combined a deficit of FOXP3(+) cells and other lymphocyte populations. METHODS We analyzed the major lymphocyte subsets and the FOXP3(+) regulatory system in blood samples obtained during the 2-year period that followed the last autoimmune manifestation. RESULTS The patient had severe naïve T lymphopenia and a major deficit of FOXP3(+)CD4(+) T cells, both in circulation and in the highly inflamed intestinal mucosa, but mutations in the FOXP3 locus were excluded. The blood FOXP3(+) pool was devoid of CD25(high) cells, but the few regulatory CD25(+) cells were functional. Intrinsic defects in the expression of CD25, FOXP3, and interleukin 2 were excluded. Upon activation, a small subset of cells, presumably committed to regulatory function, sustained expression of CD25 and FOXP3. CONCLUSIONS Peripheral T lymphopenia of both naïve and natural regulatory T cells might be the consequence of defective thymic production or the short life span of exported T cells. This case sheds new light in the etiology of autoimmune manifestations in T-cell immunodeficiencies and in the heterogeneity of AIE.
Collapse
Affiliation(s)
- Julien Zuber
- Unité du Développement des Lymphocytes, Institut Pasteur, Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
198
|
Richette P, Viguier M, Bachelez H, Bardin T. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect? J Rheumatol 2007; 34:438-9. [PMID: 17304662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Affiliation(s)
- Pascal Richette
- Department of Rhumatology, Hôpital Lariboisière, Paris, France.
| | | | | | | |
Collapse
|
199
|
Essahli M, Asri ME, Boulahna A, Zenkouar M, Viguier M, Hervaud Y, Boutevin B. New alkylated and perfluoroalkylated phosphonic acids: Synthesis, adhesive and water-repellent properties on aluminum substrates. J Fluor Chem 2006. [DOI: 10.1016/j.jfluchem.2006.03.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
200
|
Farhi D, Viguier M, Cosnes A, Reygagne P, Dubertret L, Revuz J, Roujeau JC, Bachelez H. Terbinafine-Induced Subacute Cutaneous Lupus Erythematosus. Dermatology 2006; 212:59-65. [PMID: 16319476 DOI: 10.1159/000089024] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2005] [Accepted: 07/06/2005] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Nearly 10% of lupus erythematosus (LE) are drug induced. More than 60 different drugs are involved in iatrogenic LE. We report herein 3 cases of terbinafine-induced LE. OBSERVATIONS Three patients receiving terbinafine for a suspected dermatophytic infection developed a subacute cutaneous LE, within 7 weeks following terbinafine introduction. The patients' medical history included sicca syndrome, lung carcinoma and Kikuchi disease, respectively. Clinical remission occurred within 15 weeks following terbinafine withdrawal. DISCUSSION Sixteen cases of terbinafine-induced LE have been previously reported, including 13 women. The median age was 54 years. Prior autoimmunity was reported in 10 cases, including 5 pre-existing LE. The median delay between terbinafine introduction and LE onset was 5 weeks. The median time until clinical recovery following terbinafine withdrawal was 8 weeks. CONCLUSION Terbinafine should be prescribed only in patients with proven dermatophytosis. We recommend cautious monitoring in patients with pre-existing autoimmunity. The diagnosis of terbinafine-induced LE should lead to the immediate and definitive withdrawal of the drug.
Collapse
Affiliation(s)
- David Farhi
- Department of Dermatology 1, Saint Louis Hospital, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|